• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞因子与胰腺导管腺癌:探究其与分子亚型和预后的关系。

Cytokines and Pancreatic Ductal Adenocarcinoma: Exploring Their Relationship with Molecular Subtypes and Prognosis.

机构信息

Medical Oncology Department, La Paz University Hospital, IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain.

Translational Oncology Research Laboratory, Biomedical Research Institute, La Paz University Hospital, IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain.

出版信息

Int J Mol Sci. 2024 Aug 29;25(17):9368. doi: 10.3390/ijms25179368.

DOI:10.3390/ijms25179368
PMID:39273323
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11395259/
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by its poor prognosis. The current challenge remains the absence of predictive biomarkers. Cytokines are crucial factors in the pathogenesis and prognosis of PDAC. Furthermore, there is growing interest in differentiating between molecular subtypes of PDAC. The aim of our study is to evaluate the association between the analyzed cytokines and the molecular subtypes of PDAC and to determine their prognostic value. Cytokine levels were measured in 73 patients, and molecular subtypes were analyzed in 34 of these patients. Transforming Growth Factor Beta 2 (TGF-β2) levels were independently associated with the basal-like and null subtypes. In patients with locally advanced and metastatic PDAC, elevated levels of interleukin (IL)-1α, IL-1β, IL-6, IL-8, IL-9, and IL-15 were associated with a higher risk of progression during first-line treatment, and increased levels of IL-1β, IL-6, IL-8, IL-9, and IL-15 were related to increased mortality. Furthermore, a significant association was observed between higher percentiles of IL-6 and IL-8 and shorter progression-free survival (PFS) during first-line treatment, and between higher percentiles of IL-8 and shorter overall survival (OS). In the multivariate analysis, only elevated levels of IL-8 were independently associated with a higher risk of progression during first-line treatment and mortality. In conclusion, the results of our study suggest that cytokine expression varies according to the molecular subtype of PDAC and that cytokines also play a relevant role in patient prognosis.

摘要

胰腺导管腺癌(PDAC)的预后较差。目前的挑战仍然是缺乏预测性生物标志物。细胞因子是 PDAC 发病机制和预后的关键因素。此外,人们越来越关注区分 PDAC 的分子亚型。我们的研究旨在评估分析的细胞因子与 PDAC 的分子亚型之间的关联,并确定它们的预后价值。在 73 名患者中测量了细胞因子水平,在其中 34 名患者中分析了分子亚型。转化生长因子β 2(TGF-β2)水平与基底样和空亚型独立相关。在局部晚期和转移性 PDAC 患者中,白细胞介素(IL)-1α、IL-1β、IL-6、IL-8、IL-9 和 IL-15 水平升高与一线治疗期间进展风险增加相关,IL-1β、IL-6、IL-8、IL-9 和 IL-15 水平升高与死亡率增加相关。此外,在一线治疗期间,IL-6 和 IL-8 的较高百分位数与无进展生存期(PFS)缩短之间以及 IL-8 的较高百分位数与总生存期(OS)缩短之间存在显著关联。在多变量分析中,只有升高的 IL-8 水平与一线治疗期间进展和死亡率的风险增加独立相关。总之,我们的研究结果表明,细胞因子表达根据 PDAC 的分子亚型而变化,细胞因子在患者预后中也发挥着重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11395259/9337f895f7e0/ijms-25-09368-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11395259/cf120cb4f0ad/ijms-25-09368-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11395259/4fcd63a72db5/ijms-25-09368-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11395259/4fb23f476a1a/ijms-25-09368-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11395259/1186227c06b6/ijms-25-09368-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11395259/9337f895f7e0/ijms-25-09368-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11395259/cf120cb4f0ad/ijms-25-09368-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11395259/4fcd63a72db5/ijms-25-09368-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11395259/4fb23f476a1a/ijms-25-09368-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11395259/1186227c06b6/ijms-25-09368-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fd4/11395259/9337f895f7e0/ijms-25-09368-g005.jpg

相似文献

1
Cytokines and Pancreatic Ductal Adenocarcinoma: Exploring Their Relationship with Molecular Subtypes and Prognosis.细胞因子与胰腺导管腺癌:探究其与分子亚型和预后的关系。
Int J Mol Sci. 2024 Aug 29;25(17):9368. doi: 10.3390/ijms25179368.
2
Dual and triple gene combinations of KRT5, KRT17, and S100A2 identify basal-like subtype of pancreatic ductal adenocarcinoma and correlate with survival outcome.KRT5、KRT17 和 S100A2 的双重和三重基因组合可鉴定胰腺导管腺癌的基底样亚型,并与生存结局相关。
FASEB J. 2024 Aug 15;38(15):e23867. doi: 10.1096/fj.202302484RR.
3
Combination immunohistochemistry for CK5/6, p63, GATA6, and HNF4a predicts clinical outcome in treatment-naïve pancreatic ductal adenocarcinoma.CK5/6、p63、GATA6 和 HNF4a 的联合免疫组化预测治疗初治胰腺导管腺癌的临床结局。
Sci Rep. 2024 Jul 6;14(1):15598. doi: 10.1038/s41598-024-65900-w.
4
Pancreatic ductal adenocarcinoma: Prognostic indicators of advanced disease.胰腺导管腺癌:晚期疾病的预后指标。
PLoS One. 2022 Jan 12;17(1):e0262439. doi: 10.1371/journal.pone.0262439. eCollection 2022.
5
A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.基于 PD-L2 的免疫标志物特征有助于预测可切除胰腺导管腺癌的生存情况。
J Immunother Cancer. 2019 Aug 29;7(1):233. doi: 10.1186/s40425-019-0703-0.
6
Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review.细胞因子作为胰腺导管腺癌的生物标志物:一项系统综述
PLoS One. 2016 May 12;11(5):e0154016. doi: 10.1371/journal.pone.0154016. eCollection 2016.
7
Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma.激肽释放酶相关肽酶 7 的表达可预测不可切除的胰腺导管腺癌患者的预后不良。
Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1135-42. doi: 10.1158/1055-9965.EPI-11-1079. Epub 2012 May 9.
8
Correlation of laminin subunit alpha 3 expression in pancreatic ductal adenocarcinoma with tumor liver metastasis and survival.胰腺导管腺癌中层粘连蛋白亚单位α3 的表达与肿瘤肝转移及生存的相关性。
Radiol Oncol. 2024 Mar 7;58(2):234-242. doi: 10.2478/raon-2024-0020. eCollection 2024 Jun 1.
9
Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.SHP2在胰腺导管腺癌患者中的表达及预后价值
Tumour Biol. 2016 Jun;37(6):7853-9. doi: 10.1007/s13277-015-4675-5. Epub 2015 Dec 23.
10
Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.对 1200 例胰腺导管腺癌的基因表达谱分析揭示了新的亚型。
BMC Cancer. 2018 May 29;18(1):603. doi: 10.1186/s12885-018-4546-8.

本文引用的文献

1
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
2
-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer.紫杉醇联合吉西他滨和 FOLFOX 方案治疗转移性胰腺癌。
NEJM Evid. 2024 Feb;3(2):EVIDoa2300144. doi: 10.1056/EVIDoa2300144. Epub 2024 Jan 23.
3
Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer.
靶向转化生长因子-β(TGF-β)和程序性死亡配体1(PD-L1)在胰腺癌中的治疗潜力
Curr Drug Targets. 2023;24(17):1335-1345. doi: 10.2174/0113894501264450231129042256.
4
Therapeutic role of interleukin-1 receptor antagonist in pancreatic diseases: mendelian randomization study.白介素-1 受体拮抗剂在胰腺疾病中的治疗作用:孟德尔随机研究。
Front Immunol. 2023 Sep 14;14:1240754. doi: 10.3389/fimmu.2023.1240754. eCollection 2023.
5
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.NALIRIFOX 对比 nab-紫杉醇和吉西他滨用于治疗初治转移性胰腺导管腺癌(NAPOLI 3):一项随机、开放标签、3 期临床试验。
Lancet. 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1. Epub 2023 Sep 11.
6
Mechanistic Insights into the Roles of the IL-17/IL-17R Families in Pancreatic Cancer.IL-17/IL-17R 家族在胰腺癌中的作用机制研究进展
Int J Mol Sci. 2023 Aug 31;24(17):13539. doi: 10.3390/ijms241713539.
7
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.在 PDAC 患者接受新辅助化疗后,持久细胞表型导致预后不良。
Nat Cancer. 2023 Sep;4(9):1362-1381. doi: 10.1038/s43018-023-00628-6. Epub 2023 Sep 7.
8
Tumor-derived interleukin-1 receptor antagonist exhibits immunosuppressive functions and promotes pancreatic cancer.肿瘤来源的白细胞介素-1受体拮抗剂具有免疫抑制功能并促进胰腺癌。
Cell Biosci. 2023 Aug 10;13(1):147. doi: 10.1186/s13578-023-01090-8.
9
The role of TGF-β in the tumor microenvironment of pancreatic cancer.转化生长因子-β在胰腺癌肿瘤微环境中的作用。
Genes Dis. 2022 Nov 19;10(4):1513-1524. doi: 10.1016/j.gendis.2022.10.019. eCollection 2023 Jul.
10
Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell- and CXCR3-dependent manner.双重阻断 IL-6 和 CTLA-4 可通过 T 细胞和 CXCR3 依赖性方式使胰腺肿瘤消退。
JCI Insight. 2023 Apr 24;8(8):e155006. doi: 10.1172/jci.insight.155006.